Dectection of AMACR cancer markers in urine
US7332290B2 · kind B2 · utility
20Cited by
12References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 30, 2004 |
| Grant date | Feb 19, 2008 |
| Priority date | — |
| Expiry date | Sep 12, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/813
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. The present invention also provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers. In particular, the present invention provides methods and compositions for the detection of α-methylacyl-CoA racemase (AMACR) in the urine as a marker for prostate cancer detection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.